RESUMO
BACKGROUND: Small airway inflammation and fibrosis or bronchiolitis obliterans (BO) is the predominant presentation of chronic lung allograft dysfunction (CLAD) post-lung transplantation. Carbon monoxide (CO) is a critical endogenous signaling transducer with known anti-inflammatory and anti-fibrotic effects but its therapeutic potential in CLAD remains to be fully elucidated. METHODS: Here we investigate the effect of inhaled CO in modulating chronic lung allograft rejection pathology in a murine orthotopic lung transplant model of BO (B6D2F1/JâDBA/2J). Additionally, the effects of CO on the activated phenotype of mesenchymal cells isolated from human lung transplant recipients with CLAD were studied. RESULTS: Murine lung allografts treated with CO (250 ppm × 30 minutes twice daily from days 7 to 40 post-transplantation) demonstrated decreased immune cell infiltration, fibrosis, and airway obliteration by flow cytometry, trichrome staining, and morphometric analysis, respectively. Decreased total collagen, with levels comparable to isografts, was noted in CO-treated allografts by quantitative hydroxyproline assay. In vitro, CO (250 ppm × 16h) was effective in reversing the fibrotic phenotype of human CLAD mesenchymal cells with decreased collagen I and ß-catenin expression as well as an inhibitory effect on ERK1/2 MAPK, and mTORC1/2 signaling. Sildenafil, a phosphodiesterase 5 inhibitor, partially mimicked the effects of CO on CLAD mesenchymal cells and was partially effective in decreasing collagen deposition in murine allografts, suggesting the contribution of cGMP-dependent and -independent mechanisms in mediating the effect of CO. CONCLUSION: These results suggest a potential role for CO in alleviating allograft fibrosis and mitigating chronic rejection pathology post-lung transplant.
Assuntos
Bronquiolite Obliterante , Transplante de Pulmão , Humanos , Animais , Camundongos , Monóxido de Carbono , Aloenxertos/patologia , Transplante de Pulmão/efeitos adversos , Fibrose , Pulmão/patologia , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/prevenção & controle , Colágeno , Rejeição de EnxertoRESUMO
Lung transplantation has developed significantly in recent years, but post-transplant care and patients' survival still need to be improved. Moreover, organ shortage urges novel modalities to improve the quality of unsuitable lungs. Cytokines, the chemical mediators of the immune system, might be used for diagnostic and therapeutic purposes in lung transplantation. Cytokine monitoring pre- and post-transplant could be applied to the prevention and early diagnosis of injurious inflammatory events including primary graft dysfunction, acute cellular rejection, bronchiolitis obliterans syndrome, restrictive allograft syndrome, and infections. In addition, preoperative cytokine removal, specific inhibition of proinflammatory cytokines, and enhancement of anti-inflammatory cytokines gene expression could be considered therapeutic options to improve lung allograft survival. Therefore, it is essential to describe the cytokines alteration during inflammatory events to gain a better insight into their role in developing the abovementioned complications. Herein, cytokine fluctuations in lung tissue, bronchoalveolar fluid, peripheral blood, and exhaled breath condensate in different phases of lung transplantation have been reviewed; besides, cytokine gene polymorphisms with clinical significance have been summarized.
Assuntos
Bronquiolite Obliterante , Transplante de Pulmão , Humanos , Citocinas/genética , Transplante de Pulmão/efeitos adversos , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/prevenção & controle , Rejeição de Enxerto/genética , Rejeição de Enxerto/prevenção & controle , Transplante HomólogoRESUMO
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. The aim of this study was to investigate the effect of locally augmented immunosuppression with liposomal cyclosporine A for inhalation (L-CsA-i) for the prevention of bronchiolitis obliterans syndrome (BOS). In a randomized, double-blind, placebo-controlled, multi-center Phase 3 study, 180 LT recipients in BOS grade 0 were planned to receive L-CsA-i or placebo in addition to triple-drug immunosuppression. L-CsA-i was administered twice daily via an Investigational eFlow nebulizer to recipients of single (SLT) and bilateral lung transplants (BLT) within 6-32 weeks posttransplant, and continued for 2 years. The primary endpoint was BOS-free survival. 130 patients were enrolled before the study was prematurely terminated for business reasons. Despite a 2-year actuarial difference in BOS-free survival of 14.1% in favor of L-CsA-i in the overall study population, the primary endpoint was not met (p = .243). The pre-defined per protocol analysis of SLT recipients (n = 24) resulted in a treatment difference of 58.2% (p = .053). No difference was observed in the BLT (n = 48) subpopulation (p = .973). L-CsA-i inhalation was well tolerated. Although this study failed to meet its primary endpoint, the results warrant additional investigation of L-CsA-i in lung transplant recipients.
Assuntos
Bronquiolite Obliterante , Transplante de Pulmão , Administração por Inalação , Bronquiolite Obliterante/tratamento farmacológico , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/prevenção & controle , Ciclosporina/uso terapêutico , Humanos , Pulmão , Transplante de Pulmão/efeitos adversosRESUMO
Idiopathic pulmonary fibrosis (IPF) and gastroesophageal reflux disease (GERD) are undoubtedly related. Even though it is not clear yet which one is the primary disease, they certainly interact increasing each other's severity. Symptoms are unreliable to diagnose GERD in patients with IPF, and objective evaluation with pH monitoring and/or bronchoalveolar lavage analysis is mandatory. Pharmacological treatment with proton pump inhibitors (PPIs) may bring control of IPF in few patients, but PPIs do not control reflux but just change the pH of the gastric refluxate. Surgical therapy based on a fundoplication is safe and effective as it controls any type of reflux, independently from the pH of the gastric refluxate. In patients waiting for lung transplantation (if they can tolerate a laparoscopic operation under general anesthesia), a fundoplication before the operation might block the progression of IPF, while after transplantation it might prevent rejection by preventing the bronchiolitis obliterans syndrome.
Assuntos
Refluxo Gastroesofágico/complicações , Fibrose Pulmonar Idiopática/complicações , Bronquiolite Obliterante/prevenção & controle , Lavagem Broncoalveolar , Progressão da Doença , Monitoramento do pH Esofágico , Fundoplicatura/métodos , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/tratamento farmacológico , Refluxo Gastroesofágico/cirurgia , Rejeição de Enxerto/prevenção & controle , Azia/tratamento farmacológico , Humanos , Fibrose Pulmonar Idiopática/cirurgia , Transplante de Pulmão , Inibidores da Bomba de Prótons/uso terapêutico , SíndromeRESUMO
Bronchiolitis Obliterans Syndrome seriously reduces long-term survival of lung transplanted patients. Up to now there is no effective therapy once BOS is established. Nanomedicine introduces the possibility to administer drugs locally into lungs increasing drug accumulation in alveola reducing side effects. Imatinib was loaded in gold nanoparticles (GNP) functionalized with antibody against CD44 (GNP-HCIm). Lung fibroblasts (LFs) were derived from bronchoalveolar lavage of BOS patients. GNP-HCIm cytotoxicity was evaluated by MTT assay, apoptosis/necrosis and phosphorylated-cAbl (cAbl-p). Heterotopic tracheal transplantation (HTT) mouse model was used to evaluate the effect of local GNP-HCIm administration by Alzet pump. GNP-HCIm decreased LFs viability compared to Imatinib (44.4 ± 1.8% vs. 91.8 ± 3.2%, p < 0.001), inducing higher apoptosis (22.68 ± 4.3% vs. 6.43 ± 0.29; p < 0.001) and necrosis (18.65 ± 5.19%; p < 0.01). GNP-HCIm reduced cAbl-p (0.41 GNP-HCIm, 0.24 Imatinib vs. to control; p < 0.001). GNP-HCIm in HTT mouse model by Alzet pump significantly reduced tracheal lumen obliteration (p < 0.05), decreasing apoptosis (p < 0.05) and TGF-ß-positive signal (p < 0.05) in surrounding tissue. GNP-HCIm treatment significantly reduced lymphocytic and neutrophil infiltration and mast cells degranulation (p < 0.05). Encapsulation of Imatinib into targeted nanoparticles could be considered a new option to inhibit the onset of allograft rejection acting on BOS specific features.
Assuntos
Bronquíolos/efeitos dos fármacos , Bronquiolite Obliterante/prevenção & controle , Ouro/administração & dosagem , Mesilato de Imatinib/farmacologia , Pulmão/efeitos dos fármacos , Nanopartículas Metálicas/administração & dosagem , Animais , Apoptose/efeitos dos fármacos , Bronquíolos/metabolismo , Bronquiolite Obliterante/metabolismo , Modelos Animais de Doenças , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Humanos , Receptores de Hialuronatos/metabolismo , Pulmão/metabolismo , Transplante de Pulmão/efeitos adversos , Linfócitos/efeitos dos fármacos , Linfócitos/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Traqueia/efeitos dos fármacos , Traqueia/metabolismo , Fator de Crescimento Transformador beta/metabolismoRESUMO
Chronic allograft dysfunction (CAD) resulting from fibrosis is the major limiting factor for long-term survival of lung transplant patients. Myofibroblasts promote fibrosis in multiple organs, including the lungs. In this study, we identified PLK1 as a promoter of myofibroblast differentiation and investigated the mechanism by which its inhibition alleviates transplant-associated obliterative bronchiolitis (OB) during CAD. High-throughput bioinformatic analyses and experiments using the murine heterotopic tracheal transplantation model revealed that PLK1 is upregulated in grafts undergoing CAD as compared with controls, and that inhibiting PLK1 alleviates OB in vivo. Inhibition of PLK1 in vitro reduced expression of the specific myofibroblast differentiation marker α-smooth muscle actin (α-SMA) and decreased phosphorylation of both MEK and ERK. Importantly, we observed a similar phenomenon in human primary fibroblasts. Our results thus highlight PLK1 as a promising therapeutic target for alleviating transplant-associated OB through suppression of TGF-ß1-mediated myofibroblast differentiation.
Assuntos
Bronquiolite Obliterante/patologia , Proteínas de Ciclo Celular/metabolismo , Rejeição de Enxerto/patologia , Transplante de Pulmão/efeitos adversos , Miofibroblastos/patologia , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Actinas/metabolismo , Aloenxertos/citologia , Aloenxertos/efeitos dos fármacos , Aloenxertos/patologia , Animais , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/prevenção & controle , Proteínas de Ciclo Celular/antagonistas & inibidores , Proteínas de Ciclo Celular/genética , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/genética , Células Cultivadas , Doença Crônica/prevenção & controle , Biologia Computacional , Modelos Animais de Doenças , Fibrose , Técnicas de Silenciamento de Genes , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/prevenção & controle , Voluntários Saudáveis , Humanos , Pulmão/citologia , Pulmão/efeitos dos fármacos , Pulmão/patologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Sistema de Sinalização das MAP Quinases/genética , Masculino , Camundongos , Miofibroblastos/efeitos dos fármacos , Células NIH 3T3 , Via de Pentose Fosfato/efeitos dos fármacos , Fosforilação , Cultura Primária de Células , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Serina-Treonina Quinases/genética , Proteínas Proto-Oncogênicas/antagonistas & inibidores , Proteínas Proto-Oncogênicas/genética , Pteridinas/farmacologia , Pteridinas/uso terapêutico , RNA-Seq , Traqueia/citologia , Traqueia/efeitos dos fármacos , Traqueia/patologia , Traqueia/transplante , Fator de Crescimento Transformador beta1/metabolismo , Regulação para Cima , Quinase 1 Polo-LikeRESUMO
BACKGROUND: ARS has been adopted in select patients with lung transplant for the past 2 decades in many centers. Outcomes have been reported sporadically. No pooled analysis of retrospective series has been performed. OBJECTIVE: This review and pooled analysis sought to demonstrate objective evidence of improved graft function in lung transplant patients undergoing antireflux surgery (ARS). METHODS: In accordance with Meta-analyses of Observational Studies in Epidemiology guidelines, a search of PubMed Central, Medline, Google Scholar, and Cochrane Library databases was performed. Articles documenting spirometry data pre- and post-ARS were reviewed and a random-effects model meta-analysis was performed on forced expiratory volume in 1 second (FEV1) values and the rate of change of FEV1. RESULTS: Six articles were included in the meta-analysis. Regarding FEV1 before and after ARS, we observed a small increase in FEV1 values in studies reporting raw values (2.02 ± 0.89 L/1 sec vs 2.14 ± 0.77 L/1 sec; n = 154) and % of predicted (77.1% ± 22.1% vs 81.2% ± 26.95%; n = 45), with a small pooled Cohen d effect size of 0.159 (P = .114). When considering the rate of change of FEV1 we observed a significant difference in pre-ARS compared with post-ARS (-2.12 ± 2.76 mL/day vs +0.05 ± 1.19 mL/day; n = 103). There was a pooled effect size of 1.702 (P = .013), a large effect of ARS on the rate of change of FEV1 values. CONCLUSIONS: This meta-analysis of retrospective observational studies demonstrates that ARS might benefit patients with declining FEV1, by examining the rate of change of FEV1 during the pre- and postoperative periods.
Assuntos
Fundoplicatura/métodos , Refluxo Gastroesofágico/complicações , Refluxo Gastroesofágico/cirurgia , Rejeição de Enxerto/prevenção & controle , Transplante de Pulmão , Aloenxertos , Bronquiolite Obliterante/prevenção & controle , Determinação da Acidez Gástrica , Humanos , Concentração de Íons de Hidrogênio , Testes de Função RespiratóriaRESUMO
BACKGROUND: Dysregulated airway epithelial repair following injury is a proposed mechanism driving posttransplant bronchiolitis obliterans (BO), and its clinical correlate bronchiolitis obliterans syndrome (BOS). This study compared gene and cellular characteristics of injury and repair in large (LAEC) and small (SAEC) airway epithelial cells of transplant patients. METHODS: Subjects were recruited at the time of routine bronchoscopy posttransplantation and included patients with and without BOS. Airway epithelial cells were obtained from bronchial and bronchiolar brushing performed under radiological guidance from these patients. In addition, bronchial brushings were also obtained from healthy control subjects comprising of adolescents admitted for elective surgery for nonrespiratory-related conditions. Primary cultures were established, monolayers wounded, and repair assessed (±) azithromycin (1 µg/mL). In addition, proliferative capacity as well as markers of injury and dysregulated repair were also assessed. RESULTS: SAEC had a significantly dysregulated repair process postinjury, despite having a higher proliferative capacity than large airway epithelial cells. Addition of azithromycin significantly induced repair in these cells; however, full restitution was not achieved. Expression of several genes associated with epithelial barrier repair (matrix metalloproteinase 7, matrix metalloproteinase 3, the integrins ß6 and ß8, and ß-catenin) were significantly different in epithelial cells obtained from patients with BOS compared to transplant patients without BOS and controls, suggesting an intrinsic defect. CONCLUSIONS: Chronic airway injury and dysregulated repair programs are evident in airway epithelium obtained from patients with BOS, particularly with SAEC. We also show that azithromycin partially mitigates this pathology.
Assuntos
Azitromicina/farmacologia , Bronquiolite Obliterante/prevenção & controle , Células Epiteliais/efeitos dos fármacos , Rejeição de Enxerto/prevenção & controle , Transplante de Pulmão/efeitos adversos , Adolescente , Adulto , Remodelação das Vias Aéreas/efeitos dos fármacos , Aloenxertos/citologia , Aloenxertos/diagnóstico por imagem , Aloenxertos/patologia , Azitromicina/uso terapêutico , Brônquios/citologia , Brônquios/diagnóstico por imagem , Brônquios/patologia , Bronquiolite Obliterante/diagnóstico , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/patologia , Broncoscopia , Estudos de Casos e Controles , Células Cultivadas , Criança , Avaliação Pré-Clínica de Medicamentos , Células Epiteliais/patologia , Feminino , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Cultura Primária de Células , Regeneração/efeitos dos fármacos , Transplante Homólogo , Adulto JovemRESUMO
OBJECTIVE: Bronchiolitis obliterans syndrome arising from chronic airway inflammation is a leading cause of death following lung transplantation. Several studies have suggested that inhaled hydrogen can protect lung grafts from ischemia-reperfusion injury via anti-inflammatory and -oxidative mechanisms. We investigated whether molecular hydrogen-saturated water can preserve lung allograft function in a heterotopic tracheal allograft mouse model of obliterative airway disease METHODS: Obliterative airway disease was induced by heterotopically transplanting tracheal allografts from BALB/c donor mice into C57BL/6 recipient mice, which were subsequently administered hydrogen water (10 ppm) or tap water (control group) (n = 6 each) daily without any immunosuppressive treatment. Histological and immunohistochemical analyses were performed on days 7, 14, and 21. RESULTS: Hydrogen water decreased airway occlusion on day 14. No significant histological differences were observed on days 7 or 21. The cluster of differentiation 4/cluster of differentiation 3 ratio in tracheal allografts on day 14 was higher in the hydrogen water group than in control mice. Enzyme-linked immunosorbent assay performed on day 7 revealed that hydrogen water reduced the level of the pro-inflammatory cytokine interleukin-6 and increased that of forkhead box P3 transcription factor, suggesting an enhancement of regulatory T cell activity. CONCLUSIONS: Hydrogen water suppressed the development of mid-term obliterative airway disease in a mouse tracheal allograft model via anti-oxidant and -inflammatory mechanisms and through the activation of Tregs. Thus, hydrogen water is a potential treatment strategy for BOS that can improve the outcome of lung transplant patients.
Assuntos
Bronquiolite Obliterante/prevenção & controle , Modelos Animais de Doenças , Hidrogênio , Pulmão/fisiopatologia , Traqueia/transplante , Água/administração & dosagem , Obstrução das Vias Respiratórias/etiologia , Aloenxertos , Animais , Bronquiolite Obliterante/fisiopatologia , Ensaio de Imunoadsorção Enzimática , Imunossupressores , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Transplante HomólogoRESUMO
Primary graft dysfunction (PGD) is a form of acute lung injury that develops within the first 72 hours after lung transplantation. The overall incidence of PGD is estimated to be around 30%, and the 30-day mortality for grade 3 PGD around 36%. PGD is also associated with the development of bronchiolitis obliterans syndrome, a specific form of chronic lung allograft dysfunction. In this article, we will discuss perioperative strategies for PGD prevention as well as possible future avenues for prevention and treatment.
Assuntos
Lesão Pulmonar Aguda/prevenção & controle , Transplante de Pulmão/métodos , Disfunção Primária do Enxerto/prevenção & controle , Lesão Pulmonar Aguda/epidemiologia , Lesão Pulmonar Aguda/fisiopatologia , Bronquiolite Obliterante/etiologia , Bronquiolite Obliterante/prevenção & controle , Humanos , Incidência , Assistência Perioperatória/métodos , Disfunção Primária do Enxerto/epidemiologia , Disfunção Primária do Enxerto/fisiopatologiaRESUMO
BACKGROUND: Obliterative bronchiolitis (OB) is the major complication limiting the long-term survival of allografts after lung transplantation. In this study, we investigated the effect of tacrolimus (FK506) combined with GM6001ï¼a matrix metalloproteinase (MMP) inhibitorï¼ on the formation of OB using a mouse heterotopic tracheal transplantation model. METHODS: Syngeneic tracheal grafts were transplanted heterotopically from BALB/c mice to BALB/c mice. Allografts from C57BL/6 mice were transplanted to BALB/c mice. Isograft group, allograft group, allograft+FK506 group, allograft +GM6001 group and allograft+FK506â¯+â¯GM6001 group was given respectively intraperitoneal injection of saline, saline, FK506, GM6001 and FK506â¯+â¯GM6001 once a day. At 28â¯day after transplantation, OB incidence was determined by hematoxylin-eosin staining and the expressions of MMPs and cytokines were assessed using enzyme linked immunosorbent assay, immunohistochemical assays and western blot assay. RESULTS: The tracheal occlusion rates of isograft group, allograft group, allograft+FK506 group, allograft+GM6001 group and allograft+FK506â¯+â¯GM6001 group were 0, 74.1⯱â¯9.79%, 34.4⯱â¯6.04%, 40.3⯱â¯8.77% and 26.5⯱â¯5.73% respectively. There were significant differences between the latter two groups (Pâ¯<â¯.001). The serum MMP-8 and MMP-9 levels of allograft group were significantly higher than those of isograft group (Pâ¯<â¯.05) and had no significant decrease when treated by FK506. The serum MMP-8 and MMP-9 levels of allograft+FK506â¯+â¯GM6001 group were significantly lower than those of allograft+FK506 group (Pâ¯<â¯.05). MMP-8 and MMP-9 protein expression in the grafts of allograft+FK506â¯+â¯GM6001 group were lower than those of allograft+FK506 group verified by immunohistochemical staining and western blotting. CONCLUSION: FK506 combined with GM6001 could alleviate tracheal obliteration in mouse heterotopic tracheal transplantation model, due to its inhibitory effect on MMPs.
Assuntos
Obstrução das Vias Respiratórias/prevenção & controle , Bronquiolite Obliterante/prevenção & controle , Dipeptídeos/uso terapêutico , Transplante de Pulmão , Complicações Pós-Operatórias/prevenção & controle , Tacrolimo/uso terapêutico , Traqueia/patologia , Animais , Bronquiolite Obliterante/etiologia , Modelos Animais de Doenças , Quimioterapia Combinada , Sobrevivência de Enxerto , Humanos , Masculino , Metaloproteinase 8 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Traqueia/transplante , Transplante Heterotópico , Transplante HomólogoRESUMO
Post-infectious bronchiolitis obliterans (BOPI) is a chronic obstructive disease, resulting from an acute injury and an abnormal repair process, with diffuse pulmonary fibrosis and peribronchiolar fibrosis, which cause chronic respiratory failure with prolonged oxygen dependence. The most common cause of this disease is severe bronchiolitis / pneumonia due to adenovirus (ADV), mainly in group B, before 2 years of age. In its pathogenesis are factors of the host and the characteristics of the virus that has mechanisms to prevent immunity and cause a chronic infection with great inflammatory response. This involves numerous cells (mainly lymphocytes) and cytokines that are produced by a chronic infection by ADV, which maintains a prolonged inflammatory process, determining different degrees of lung damage. In this article we will discuss the mechanisms by which this damage occurs.
La bronquiolitis obliterante postinfecciosa (BOPI) es una enfermedad obstructiva crónica, resultante de una injuria aguda y un proceso de reparación anómalo, con fibrosis pulmonar y peribronquiolar difusa, que causan insuficiencia respiratoria crónica con dependencia de oxigeno prolongada. La causa más frecuente de esta enfermedad es una bronquiolitis/neumonía grave por adenovirus (ADV), principalmente del grupo B, antes de los 2 años de vida. En su patogenia intervienen factores del huésped y las características del virus que tiene mecanismos para evitar la inmunidad y provocar una infección crónica con gran respuesta inflamatoria. En esta participan numerosas células (principalmente linfocitos) y citoquinas que se producen por una infección crónica por ADV, lo que mantiene un proceso inflamatorio prolongado, determinando distintos grados de daño pulmonar. En este artículo abordaremos los mecanismos por los cuales se produce este daño.
Assuntos
Humanos , Criança , Bronquiolite Obliterante/etiologia , Pneumonia Viral/complicações , Bronquiolite Obliterante/prevenção & controle , Bronquiolite Obliterante/epidemiologia , Infecções por Adenovirus Humanos/complicações , Fatores de RiscoRESUMO
Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeated 7 questions on first-line treatment and 3 questions on second-line scenarios followed by an updated survey on all current systemic treatment options known and applied, with 29 of 66 centers (43%) responding. In summary, the results show a large overlap of first-line treatment practice between centers and the 2 surveys because of a lack of new data that changes practice, except significant heterogeneity of treatment of cGVHD progressive onset type, which can be explained by the lack of trials focusing on this high-risk entity. In contrast, treatment options applied to second-line therapy vary considerably, with new agents like ibrutinib and ruxolitinib entering clinical practice. Moreover, treatment of bronchiolitis obliterans syndrome demonstrates heterogeneity in applied therapeutic options and sequence because of a lack of controlled data and different conclusions from already existing evidence. In summary, the survey results demonstrate an increasing number of treatment options applied to cGVHD accompanied by a significant heterogeneity in second-line treatment and underline the urgent need for clinical trials and registry analyses on rare entities with high mortality like progressive onset type and lung involvement of cGVHD.
Assuntos
Bronquiolite Obliterante , Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Terapia de Imunossupressão , Pirazóis/administração & dosagem , Pirimidinas/administração & dosagem , Adenina/análogos & derivados , Adulto , Áustria/epidemiologia , Bronquiolite Obliterante/epidemiologia , Bronquiolite Obliterante/prevenção & controle , Doença Crônica , Feminino , Alemanha/epidemiologia , Doença Enxerto-Hospedeiro/epidemiologia , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Masculino , Nitrilas , Piperidinas , Suíça/epidemiologiaRESUMO
Chronic lung allograft dysfunction (CLAD) still remains a major drawback in the outcome following lung transplantation (LTx). New therapeutic strategies are warranted. Growth factors and their receptors like platelet-derived growth factor-receptor (PDGFR) and vascular endothelial growth factor-receptor (VEGFR), may play a crucial role in the development of CLAD, especially bronchiolitis obliterans (BO) and vasculopathy. In this study, we used an orthotopic left lung transplantation model from Fischer (F344) to Wystar Kyoto (WKY) rats to investigate the effect of the receptor tyrosine kinase inhibitor (RTKI) vatalanib alone, the dual combination of vatalanib and imatinib and a triple therapy consisting of vatalanib, imatinib and the mammalian target of rapamycin inhibitor (mTORI) everolimus on the development of CLAD after LTx in rats. With this trial we demonstrated that monotherapy with vatalanib attenuated mild and severe chronic vascular rejection, whereas dual therapy (vatalanib and imatinib) after LTx also showed a significant reduction of chronic bronchiolar rejection and interstitial fibrosis. By adding everolimus, the effect of vatalanib and imatinib could additionally be increased. In conclusion, the combination of mTORI and RTKIs might be a possible strategy in the prevention of CLAD and BO.
Assuntos
Everolimo/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Mesilato de Imatinib/uso terapêutico , Transplante de Pulmão , Ftalazinas/uso terapêutico , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Animais , Bronquiolite Obliterante/patologia , Bronquiolite Obliterante/prevenção & controle , Sinergismo Farmacológico , Fibrose , Rejeição de Enxerto/patologia , Imuno-Histoquímica , Ratos , Ratos Endogâmicos F344 , Ratos Endogâmicos WKY , Receptores Proteína Tirosina Quinases/antagonistas & inibidores , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/metabolismo , Serina-Treonina Quinases TOR/antagonistas & inibidores , Transplante Homólogo , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismoRESUMO
Bronchiolitis obliterans syndrome (BOS) is a rare pulmonary complication of hematopoietic stem cell transplantation (HSCT) with high mortality. Chronic bacterial airway infection (CAI) causes exacerbation and progression of several airway diseases, and bacterial airway colonization was shown to be associated with BOS after lung transplantation.We assessed the association between CAI and clinical course in patients with BOS after HSCT. This retrospective study included 910 patients undergoing allogeneic HSCT between 2005 and 2013 at our institution. BOS diagnosis was reevaluated according to the 2014 US National Institutes of Health criteria. Sputum and bronchial lavage culture results, pulmonary function, and survival were compared between patients with and without CAI.Median follow-up was 974.5 (261.5-2748.5) days. BOS was diagnosed in 27 (3.0%) patients, including 18 males. Median age at BOS diagnosis was 45 (40.5-58) years. Nine patients had ≥2 positive sputum cultures for bacteria or one positive bronchial lavage culture for nontuberculous mycobacteria (CAI+), whereas 9 patients had negative sputum/bronchial lavage culture or only one positive sputum culture (CAI-). Median change in forced expiratory volume in 1 s within 6 months after BOS diagnosis and overall survival were significantly worse in CAI+ patients than in CAI- patients (-250 vs +260 mL, Pâ=â.002, and 1340 days vs not reached, Pâ=â.04, respectively). No other factors including patient demographics or transplant protocol affected prognosis. There were no differences in clinical characteristics of patients with and without CAI, except for the time from transplantation to BOS diagnosis (214 vs 768 days for CAI+ and CAI-, respectively; Pâ=â.02).CAI was associated with worse outcomes in patients with BOS after HSCT. Further prospective studies should assess the association between the airway microbiome and changes in pulmonary function after HSCT to improve prognosis.
Assuntos
Bronquiolite Obliterante/mortalidade , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Pulmão/fisiopatologia , Infecções Respiratórias/microbiologia , Adulto , Bronquiolite Obliterante/complicações , Bronquiolite Obliterante/diagnóstico , Bronquiolite Obliterante/prevenção & controle , Líquido da Lavagem Broncoalveolar/microbiologia , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Testes de Função Respiratória/métodos , Infecções Respiratórias/complicações , Estudos Retrospectivos , Fatores de Risco , Escarro/microbiologia , Análise de SobrevidaRESUMO
Immunosuppression therapies including corticosteroids fail to prevent bronchiolitis obliterans syndrome (BOS), primarily a disease of the small airways, following lung transplantation. We reported increases in steroid-resistant proinflammatory lymphocytes and their loss of histone deacetylase 2 (HDAC2), an important mediator of steroid action, in the blood of stable lung transplant recipients. We noted similar increases in the steroid-resistant lymphocytes in both the blood and small airways in BOS compared with the large airways. We hypothesized that these small airway cells would also exhibit a loss of HDAC2, and that these changes could be reversed by treatment with theophylline (HDAC2 activator). Blood, bronchoalveolar lavage and large and small airway brushings were collected from lung transplant patients with BOS (n = 12) or stable lung function (n = 18) and healthy aged-matched controls (n = 13). Intracellular proinflammatory cytokines [interferon (IFN-γ) and tumour necrosis factor (TNF)-α and HDAC2 were measured in CD8+ T, natural killer (NK) T-like and NK cells from cultured small airway brushings ± 5 mg/l theophylline ± 1 µM prednisolone using flow cytometry. Increased small airway CD8 T, NK T-like and NK cells were identified in BOS versus stable transplant and controls. In BOS, these cells exhibited increased IFN-γ/TNF-α and a loss of HDAC2. HDAC2 expression by small airway CD8+ T cells correlated with forced expiratory volume in 1 s (FEV1 ) (R = 0·880, P = 0·031). Theophylline and prednisolone synergistically up-regulated HDAC2 in CD8+ T cells. BOS is associated with loss of HDAC2 from steroid-resistant proinflammatory CD8+ T, NK T-like and NK cells in the small airways. Therapeutically increasing HDAC2 in these lymphocytes may reduce steroid resistance and improve graft survival.
Assuntos
Broncodilatadores/farmacologia , Linfócitos T CD8-Positivos/metabolismo , Histona Desacetilase 2/metabolismo , Células Matadoras Naturais/metabolismo , Alvéolos Pulmonares/imunologia , Teofilina/farmacologia , Bronquiolite Obliterante/patologia , Bronquiolite Obliterante/prevenção & controle , Linfócitos T CD4-Positivos/imunologia , Sobrevivência de Enxerto/efeitos dos fármacos , Histona Desacetilase 2/análise , Humanos , Interferon gama/análise , Transplante de Pulmão/efeitos adversos , Pessoa de Meia-Idade , Prednisolona/farmacologia , Fator de Necrose Tumoral alfa/análiseRESUMO
Lung transplants belong in the group of organ transplants with poorer outcomes, with acute rejection and bronchiolitis obliterans being cited as major causes of this. Poor allograft evolution has been associated with multiple factors, including those related to esophagogastric disease. In patients with end-stage pulmonary conditions eligible for a lung transplant gastroesophageal reflux (GER), esophageal dysmotily, and gastroparesis are highly prevalent and worsen upon transplantation, which may compromise transplant viability. High-resolution impedance manometry and long-term impedance pH-metry studies provide a new perspective where reflux and dysmotility share the limelight with changes in the diagnostic approach and in potential therapies.
Assuntos
Bronquiolite Obliterante/etiologia , Acalasia Esofágica/complicações , Junção Esofagogástrica/fisiopatologia , Refluxo Gastroesofágico/complicações , Transplante de Pulmão , Complicações Pós-Operatórias/etiologia , Bronquiolite Obliterante/prevenção & controle , Acalasia Esofágica/diagnóstico , Acalasia Esofágica/terapia , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/terapia , Humanos , Complicações Pós-Operatórias/prevenção & controle , Fatores de RiscoRESUMO
BACKGROUND: Although the presence of donor-specific antibodies (DSA) is known to impact lung allograft, limited data exist regarding DSA management. METHODS: We did a retrospective study at our center evaluating DSA management in adult lung transplant recipients undergoing lung transplantation between January 1, 2010 and June 30, 2014. Study follow-up was completed through October 2017. All recipients were stratified into 2 groups based on the presence or absence of DSA. Those with DSA were evaluated for the impact of treatment of DSA. The primary outcomes were postlung transplant survival and freedom from bronchiolitis obliterans syndrome (BOS), subset of chronic lung allograft dysfunction (CLAD). Simon-Makuch method was used to estimate overall survival and BOS-free survival to account for DSA as time-dependent covariate. Survival differences between the groups were analyzed using time-dependent Cox proportional hazards model. RESULTS: Sixty-four percent of 194 total subjects developed post-lung transplant DSA. Overall survival was different with worse survival in the DSA positive group that never cleared DSA (P = .002). BOS-free survival was lower, but did not reach significance in this group. Response to treatment was poor, with only 12 of 47 (25.5%) who received treatment demonstrating clearance of DSA. CONCLUSIONS: Donor-specific antibodies prevalence is high after lung transplantation. Clearance of DSA correlated with improved outcomes. Current therapeutic strategies against DSA are relatively ineffective. Multicenter collaborative studies will be required to evaluate current treatment strategies and other innovative modalities.
Assuntos
Bronquiolite Obliterante/imunologia , Bronquiolite Obliterante/prevenção & controle , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/prevenção & controle , Isoanticorpos/imunologia , Transplante de Pulmão/efeitos adversos , Doadores de Tecidos , Bronquiolite Obliterante/epidemiologia , Feminino , Seguimentos , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Taxa de SobrevidaRESUMO
Chronic rejection is the Achilles heel of modern lung transplantation, characterized by a slow, progressive decline in allograft function. Clinically, this manifests as obstructive disease, restrictive disease, or a mixture of the 2 depending on the underlying pathology. The 2 major phenotypes of chronic rejection include bronchiolitis obliterans syndrome and restrictive allograft syndrome. The last decade of research has revealed that each of these phenotypes has a unique underlying pathophysiology which may require a distinct treatment regimen for optimal control. Insights into the intricate alloimmune pathways contributing to chronic rejection have been gained from both large and small animal models, suggesting directions for future research. In this review, we explore the pathological hallmarks of chronic rejection, recent insights gained from both clinical and basic science research, and the current state of animal models of chronic lung rejection.
Assuntos
Bronquiolite Obliterante/diagnóstico , Bronquiolite Obliterante/fisiopatologia , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/fisiopatologia , Transplante de Pulmão/efeitos adversos , Aloenxertos , Animais , Bronquiolite Obliterante/imunologia , Bronquiolite Obliterante/prevenção & controle , Doença Crônica , Modelos Animais de Doenças , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Imunossupressores/farmacologia , Fatores de Risco , SíndromeRESUMO
BACKGROUND: Survival after lung transplantation (LTx) is often limited by bronchiolitis obliterans syndrome (BOS). METHOD: Survey of 278 recipients who underwent LTx. The endpoint used was BOS (BOS grade ≥ 2), death or Re-lung transplantation (Re-LTx) assessed by competing risk regression analyses. RESULTS: The incidence of BOS grade ≥ 2 among double LTx (DLTx) recipients was 16 ± 3% at 5 years, 30 ± 4% at 10 years, and 37 ± 5% at 20 years, compared to single LTx (SLTx) recipients whose corresponding incidence of BOS grade ≥ 2 was 11 ± 3%, 20 ± 4%, and 24 ± 5% at 5, 10, and 20 years, respectively (p > 0. 05). The incidence of BOS grade ≥ 2 by major indications ranked in descending order: other, PF, CF, COPD, PH and AAT1 (p < 0. 05). The mortality rate by major indication ranked in descending order: COPD, PH, AAT1, PF, Other and CF (p < 0. 05). CONCLUSION: No differences were seen in the incidence of BOS grade ≥ 2 regarding type of transplant, however, DLTx recipients showed a better chance of survival despite developing BOS compared to SLTx recipients. The highest incidence of BOS was seen among CF, PF, COPD, PH, and AAT1 recipients in descending order, however, CF and PF recipients showed a better chance of survival despite developing BOS compared to COPD, PH, and AAT1 recipients.